Moore RD - Search Results

1

The economic burden of late entry into medical care for patients with HIV infection.

Fleishman JA, Yehia BR, Moore RD, Gebo KA; HIV Research Network. Fleishman JA, et al. Among authors: moore rd. Med Care. 2010 Dec;48(12):1071-9. doi: 10.1097/MLR.0b013e3181f81c4a. Med Care. 2010. PMID: 21063228 Free PMC article.

2

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

3

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

4

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Among authors: moore rd. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

5

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

6

Treatment of HIV infection in the older patient.

Gebo KA, Moore RD. Gebo KA, et al. Among authors: moore rd. Expert Rev Anti Infect Ther. 2004 Oct;2(5):733-43. doi: 10.1586/14789072.2.5.733. Expert Rev Anti Infect Ther. 2004. PMID: 15482236 Review.

7

Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy?

Himelhoch S, Moore RD, Treisman G, Gebo KA. Himelhoch S, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1457-63. doi: 10.1097/01.qai.0000136739.01219.6d. J Acquir Immune Defic Syndr. 2004. PMID: 15602123

8

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103. doi: 10.1097/00126334-200501010-00017. J Acquir Immune Defic Syndr. 2005. PMID: 15608532

9

An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Moore RD, Keruly JC, Gebo KA, Lucas GM. Moore RD, et al. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):195-8. J Acquir Immune Defic Syndr. 2005. PMID: 15905736

10

High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States.

Gebo KA, Fleishman JA, Reilly ED, Moore RD; HIV Research Network. Gebo KA, et al. Among authors: moore rd. Med Care. 2005 Sep;43(9 Suppl):III23-30. doi: 10.1097/01.mlr.0000175631.34438.1e. Med Care. 2005. PMID: 16116306

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

930 results

Search Page

Filters